| Body: |
Liver transplantation remains a crucial treatment modality for patients with end-stage liver disease due to chronic hepatitis B virus (HBV) infection. However, optimal pre-transplant preparation is essential to improve post-transplant outcomes and minimize HBV recurrence. This talk will explore the hepatologistâ??s approach in preparing HBV-infected recipients for transplantation, covering key aspects such as disease assessment, antiviral therapy, risk stratification, and strategies to prevent HBV reactivation. The role of nucleos(t)ide analogs, hepatitis B immunoglobulin (HBIG), and emerging antiviral strategies will be discussed in the context of current international guidelines, including those from AASLD, EASL, and APASL. Additionally, special considerations in patients with hepatocellular carcinoma (HCC) and those with co-infections will be highlighted. By addressing these critical elements, this session aims to provide a structured approach to optimize patient selection, improve transplant success, and enhance long-term graft survival in HBV recipients. |
